UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2020

CATALYST BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

Delaware	000-51173	56-2020050
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

611 Gateway Blvd, Suite 710, South San Francisco, CA 94080
(Address of principal executive offices)

(650) 871-0761
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	**CBIO**	**Nasdaq**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On November 17, 2020, Catalyst Biosciences, Inc. (the "Company") posted an update to its corporate presentation (the "Presentation") on its website, ir.catalystbiosciences.com/presentations-events. A copy of the Presentation is attached hereto as Exhibit 99.1.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Current Report shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Presentation slide deck.
104	Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CATALYST BIOSCIENCES, INC.

Date: November 17, 2020

/s/ Clinton Musil
Clinton Musil
Chief Financial Officer

CATALYST BIOSCIENCES

Corporate Overview

17 November 2020

CatalystBiosciences.com

Forward looking statements

This presentation includes forward-looking statements that involve substantial risks and uncertainties All statements included in this presentation, other than statement of historical facts, are forward-looking statements. Forward-looking statements include statements about the potential benefits of products based on Catalyst's engineered protease platform; potential markets for and advantages of MarzAA and DalcA; plans in Q4 2020 to enroll a pivotal Phase 3 registration study of MarzAA , initiate a Phase 1/2 trial in FVII Deficiency, Glanzmann Thrombasthenia, and patients treated with Hemlibra; the potential for MarzAA and DalcA to effectively and therapeutically treat hemophilia subcutaneously; potential markets for our anticomplement and gene therapy programs; potential payments from Biogen; plans to declare a development candidates in our systemic complement program in Q4 2020; the superiority of CB 2679d-GT over other gene therapy candidates; and the Company's collaboration with Biogen for the development and commercialization of pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry age-related macular degeneration (AMD). Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements.

Various important factors could cause actual resu
materially, including, but not limited to, the risk tha
may be delayed as a result of the novel coronavir
outbreak and other factors, that trials may not hav
outcomes, that additional human trials will not rep
from earlier trials, that potential adverse effects m
testing or use of DalcA or MarzAA, including the g
neutralizing antibodies, which has been observed
with DalcA, the risk that costs required to develop
Company's products will be higher than anticipate
result of delays in development and manufacturin
COVID-19 and other factors, the risk that Biogen
Catalyst's agreement, competition and other risks
"Risk Factors" section of the Company's quarterly
Securities and Exchange Commission on Novem
other filings with the Securities and Exchange Co
Company does not assume any obligation to upd
looking statements, except as required by law.

Catalyst Biosciences – Protease medicines



Harnessing the catalytic power of proteases

One protease molecule regulates 1000s of target molecules



An adaptable protease platf

- **Demonstrated efficacy of clinica**
- Functionally enhanced natural prot
- Engineered novel protein degrader
- Ideal for high concentration drug ta amplification cascades
- Potential to address novel targets
- Increased potency and extended h

Pipeline



Investment highlights

Novel subcutaneous factors with orphan drug designation; MarzAA & DalcA – P2 efficacy in prophylaxis studies complete

Multibillion-dollar market opportunities

Strong balance sheet, $104M cash – Q3

Anti-C3 Dry AMD

SQ systemic com
regulator researc

Experienced tear

178 worldwide pa
CBIO retains full
of all compounds

Marzeptacog alfa (activated): MarzAA rFVIIa

Addresses a clear unmet need in hemophilia & other bleeding disorder



9-fold higher activity *vs* NovoSev

+ Potency allows for SQ dosing that pro
+ Simple, small volume SQ administrati

Preclinical efficacy of SQ on-den

+ HA mouse after tail cut; HA dog; HA r

P2/3 prophylaxis efficacy & safet with inhibitors

+ 46 patients treated including: single d doses/day, & daily SQ up to 97 days

SQ MarzAA is a large commercial opportunity

Global NovoSeven sales breakdown by indication (2019)



- Hem A Inh (47%)
- Hem B Inh (11%)
- Other (22%)
- FVII Def (5%)
- Glanzmann (7%)
- AHA (8%)

Source: Adivo Associates market research; Catalyst Biosciences market research. Data on file

SQ MarzAA has a superior prof

- Faster & easier to administer *vs* N every 2 hours IV until hemostasis
- MarzAA SQ half-life ~8x longer th
- 9-fold higher activity *vs* N7
- Potential to reduce rebleeding
- Stops bleeding in multiple preclin
- Can be combined with Hemlibra *in vitro* without increased thrombo
- Ideal for pediatrics and patients w access issues
- Prophylaxis efficacy demonstrate

MarzAA could be the first prophylaxis for Glanzmann & F



Global NovoSeven on demand sales Glanzmann, FVIID

Unmet need in prophylaxis

Growing number of Glan and FVIID patients treate NovoSeven



9% total increase in patients over 3 years

Source: Catalyst Biosciences, Adivo Associates Market Research, Data on file. *Note: Treated patients may be counted multiple times as patients may have multiple bleedi events per year needing factor treatment

MarzAA is efficacious with daily prophylaxis

Phase 2: Daily SQ dosing for 44 – 97 days

Annualized bleed rate
n = 9



Proportion of days with bleeding
n = 9



+ Greater thar
all bleeding
+ 2 subjects h
from 30 to 6
+ Safe & well
(6/517 dose

Mahlangu *et al.* EAHAD 2020

Current bypass agents require multiple IVs over the course o



Source: [1]NovoSeven PI Rev 7/2020; [2]Adivo Associates market research; [3]Catalyst Biosciences market research. Data on file

MAA-102: PK MarzAA levels support SQ treatment of a blee

8 subjects at each dose level



+ Target of 24-120 ng bleed is based on c infusion levels of N hemostasis during s
+ Target levels are ra
+ Target levels can be 18 hours with a sing 60 µg/kg
+ No ADA

Neuman *et al.* ISTH 2020

Crimson 1 Phase 3 study: Treatment of episodic bleeding

Hemophilia A or B with inhibitors, ABR ≥ 8



- **Primary endp**
  Non-inferior hem
  standard 4-point
- **Secondary e**
  Time to bleed re
  number of doses
- **Safety**
  Adverse events,
  antibodies (ADA

Statistics

+ **SOC estimate**
  Excellent/gooc
  bleeds
+ Non-inferiority
+ **2.5%** significa
+ **90%** power

MAA-202 Phase 1/2 study design

FVII deficiency, Glanzmann thrombasthenia and HA on Hemlibra: N = 8



- **Phase 1**

  Primary endpoint:
  Pharmacokinetics

  Secondary endpoi
  Pharmacodynamics

- **Phase 2 ToB**

  Primary endpoint:
  Hemostatic efficacy

  Secondary endpoi
  Effective hemostasi
  timepoints; doses n
  rescue meds

  Safety:
  Adverse events and

Dalcinonacog alfa: novel FIX replacement for SQ delivery



Three amino acid substitutions

+ 22-fold increased potency *vs* Benef

Differentiated from marketed IV

+ Small volume SQ administration
+ Enhanced pharmacokinetics with p
+ Excellent extravascular distribution
+ Potential to maintain continuous pr

DalcA P2b demonstrated efficacy & safety

Target levels >12% achieved with daily SQ 100 IU/kg dosing for 28 days



+ Dosed 6 severe
  - Subject 102 wi
+ **Steady state FI**
  27% achieved a
+ **No breakthrou**
+ **No neutralizing**
+ Mild to moderat
  self-limiting
+ Terminal half-lif
  2.5 - 5.1 days

Catalyst's CB 2679d gene therapy for hemophilia B

FIX Transgene	AAV Capsid	Study Dose (vg/kg)	FIX Activity (U/mL)
CB 2679d-GT	**Novel Chimeric**	**$8.0x10^{10}$**	**20**
Padua	TAK-748*	$7.4x10^{11}$	20
Padua	TAK-748*	$7.4x10^{10}$	1

*Weiller *et al.* (2019) *Blood* Vol. 134, Supplement S1 P4633

Stanford University License & sponsored research agreement

CB 2679d-GT has a sup Padua in preclinical stu

+ Stable high activity levels wi in mouse model
+ 4 to 5-fold reduction in bleed compared to the Padua
+ Potential for improved effica reduced dose

Achieved high initial FI in NHP

+ Presented at World Federati Virtual Summit 2020
+ Additional vector optimizatio studies ongoing

Wholly-owned & issue covering gene therapy

Targeting complement – a pathway regulated by proteases

Dysregulated complement activity is associated with a broad range of disorders a logical fit for our protease platform



CB 2782-PEG long acting anti-C3 protease

Best-in-class anti-C3 profile for dry AMD with dosing every 3 to 4 months

Non-Human Primates (vitreous)



Human Modelin



Predicted >90% elimination of C3 at 4 months

CB 2782-PEG: Complement factor 3 (C3) cleaving proteas

Geographic atrophy in dry AMD can result in blindness

+ Geographic atrophy is an advanc
  dry age-related macular degenera
+ dAMD affects ~1M people in the U
  5M worldwide
+ Global market estimated at >$5B
+ C3 is the only clinically validated t
  (randomized P2) for the treatment
+ No currently approved therapy

Sources: National Eye Institute. Facts About Age-Related Macular Degeneration, Tufail 2015, The Eye Diseases Prevalence Research Group 2004, Glob

CB 2782-PEG long acting anti-C3 protease

Best-in-class anti-C3 profile for dry AMD

+ Generated from Catalyst's proprietary **protease engineering platform**
+ Potent, selective and long acting anti-C3 protease that degrades C3 into inactive fragments
+ Preclinical NHP PK & PD data* predict **best-in-class** human intravitreal dosing three or four times a year

Biogen collaboration

+ Announced December 2019
+ $15M upfront, up to $340M in mi
  tiered royalties up to low double
+ Catalyst to perform fully funded p
  manufacturing activities
+ Biogen responsible for IND-enab
  worldwide clinical development
  & commercialization

*Furfine *et al.* ARVO 2019

CB 4332 SQ long-acting systemic complement regulator

Non-human primate PK supports weekly SQ dosing in humans



Expanding the compleme

+ Leverages Catalyst's proprie **engineering platform**
+ Designed for **SQ administra improved bioavailability**
+ **Simple & efficient** productio
+ Program update in Q4

Milestones – 2020



Team

Nassim Usman, Ph.D.
President & CEO

RPI · Sirna Therapeutics · PRINCIPIA · Massachusetts Institute of Technology

***28** years in biotech*

Grant Blouse, Ph.D.
SVP Translational Research

novo nordisk · Henry Ford Health System · CATALYST BIOSCIENCES

***13** years in biotech*

Clinton Musil, M.B.A
Chief Financial Officer

Personalis · ARMO BIOSCIENCES · FW Healthcare Partners

***16** years in biotech & investing/banking*

Jeffrey Landau, M.B.A.
SVP Business Development

Jazz Pharmaceuticals · ONYX PHARMACEUTICALS · Lilly

***18** years in biotech*

Howard Levy, M.B.B.Ch., Ph.D.
Chief Medical Officer

Sangart · novo nordisk · CSL · Lilly · Inspiration BIOPHARMACEUTICALS

***20** years in hematology*

Anju Chatterji, Ph.D.
SVP Biologics Development & Manufactur

GRIFOLS · NOVARTIS · BAYER

***19** years in biotech*

Summary

Disruptive approach to billion-dollar markets – protease engineering p

FVIIa: SQ MarzAA ~$2.2B market

+ P1 PK/PD & preclinical data supports ToB
+ P2 efficacy & safety demonstrated
+ P3 patient enrollment in Q4 2020

FIX: SQ DalcA >$1.8B market

+ Phase 2b efficacy & safety demonstrated
+ Potential for less frequent dosing

FIX Gene Therapy: CB 2679d-GT

+ Proprietary preclinical gene therapy asset with superior activity and lower dose *vs* current clinical constructs

Anti-C3 dAMD: IVT CB 2782-PI

+ Biogen collaboration
+ $15M upfront, up to $340M in milest double digits tiered royalties

SQ systemic complement inhi

+ Large $B+ rare-disease opportunity
+ Multiple indications & applications
+ 1st development candidate in Q4 202

Well capitalized

+ Cash runway into 2022

THANK YOU

Nasdaq: CBIO

CatalystBiosciences.com